Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis

BACKGROUND: Pancreatic cancer ranks as the fourth leading cause of cancer-related mortality in the USA. And gemcitabine has been the standard of care for advanced pancreatic cancer. However, a combined use of gemcitabine plus cisplatin (GemCis) has shown promising efficacies in pancreatic cancer pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Guoqing, Liu, Zhipeng, Huang, Shengfu, Li, Qianglong, Xiong, Li, Miao, Xiongying, Wen, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772457/
https://www.ncbi.nlm.nih.gov/pubmed/26927942
http://dx.doi.org/10.1186/s12957-016-0813-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772457/
https://www.ncbi.nlm.nih.gov/pubmed/26927942
http://dx.doi.org/10.1186/s12957-016-0813-9

Ejemplares similares